基本信息
浏览量:6
职业迁徙
个人简介
Dr. Jun Ishihara is a Lecturer (equivalent to Assistant Professor in the USA) in the Department of Bioengineering at Imperial College London. The Ishihara laboratory works in the field of protein engineering, with research foci in cancer immunotherapy, autoimmunity, and regenerative medicine.
Dr. Ishihara received his PhD in stem cell biology from the University of Tokyo. He then conducted postdoctoral training in the laboratory of Jeffrey Hubbell first at the Ecole Polytechnique Fédérale de Lausanne (EPFL) in Switzerland from 2014 to 2016 and then at the University of Chicago from 2016 to 2020 when the laboratory relocated to the Pritzker School of Molecular Engineering.
Dr. Ishihara has developed novel technologies in the field of immuno-engineering in order to improve current therapies and discover new drugs. He has developed novel approaches to cancer immunotherapy that achieve localised immune activation by targeting the tumour microenvironment. These methods make cancer immunotherapy safe and effective. Dr. Ishihara has also engineered treatments for autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. In the field of regenerative medicine, he has developed novel approaches to efficiently deliver growth factors to the wound site to promote wound healing.
Dr. Ishihara has co-authored 19 scientific papers and 16 patents, with publications in Nature Biomedical Engineering, Science Translational Medicine, Science Advances, Blood and Nature Communications. He is also a co-founder of Arrow Immune Inc., focusing on clinical translation of cancer immunotherapy techniques, HeioThera Inc., focusing on clinical translation of anti-inflammatory the therapeutics, and ScienceLounge LLC., which runs a science bar in Tokyo for scientific outreach activities.
Dr. Ishihara received his PhD in stem cell biology from the University of Tokyo. He then conducted postdoctoral training in the laboratory of Jeffrey Hubbell first at the Ecole Polytechnique Fédérale de Lausanne (EPFL) in Switzerland from 2014 to 2016 and then at the University of Chicago from 2016 to 2020 when the laboratory relocated to the Pritzker School of Molecular Engineering.
Dr. Ishihara has developed novel technologies in the field of immuno-engineering in order to improve current therapies and discover new drugs. He has developed novel approaches to cancer immunotherapy that achieve localised immune activation by targeting the tumour microenvironment. These methods make cancer immunotherapy safe and effective. Dr. Ishihara has also engineered treatments for autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. In the field of regenerative medicine, he has developed novel approaches to efficiently deliver growth factors to the wound site to promote wound healing.
Dr. Ishihara has co-authored 19 scientific papers and 16 patents, with publications in Nature Biomedical Engineering, Science Translational Medicine, Science Advances, Blood and Nature Communications. He is also a co-founder of Arrow Immune Inc., focusing on clinical translation of cancer immunotherapy techniques, HeioThera Inc., focusing on clinical translation of anti-inflammatory the therapeutics, and ScienceLounge LLC., which runs a science bar in Tokyo for scientific outreach activities.
研究兴趣
论文共 75 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Cell reports. Medicineno. 11 (2023): 101289-101289
Journal for ImmunoTherapy of Cancerno. Suppl 1 (2023)
引用0浏览0引用
0
0
CANCER SCIENCE (2023): 1398-1398
引用0浏览0引用
0
0
The Journal of pathologyno. 5 (2023): 533-550
Molecular Cancer Therapeuticsno. 12_Supplement (2023)
引用0浏览0引用
0
0
Journal for ImmunoTherapy of Cancerno. Suppl 1 (2023)
引用0浏览0引用
0
0
Journal for ImmunoTherapy of Cancerno. Suppl 1 (2023)
引用0浏览0引用
0
0
biorxiv(2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn